us-fda-guidance-454c961274dbf452773e7a2a2f4d5ed1•Quality Control Practices for Compliance with the Federal Laser Performance Standard
Quality Control Practices for Compliance with the Federal Laser Performance Standard
us-fda-guidance-454c961274dbf452773e7a2a2f4d5ed1Quality Control Practices for Compliance with the Federal Laser Performance StandardGuidance
Administrative guidance, not enacted legislation. This captured publisher edition preserves the listed document and attachments; later developments are not independently consolidated.
- Docket Number:
- FDA-2020-D-0957
- Issued by:
- Guidance Issuing OfficeCenter for Devices and Radiological Health
The Performance Standard for Laser Products (21 CFR 1040.10 and 1040.11) became effective August 2, 1976. Lasers and products containing lasers manufactured on or after that date must conform to the applicable provisions of the standard. In addition, manufacturers will be required to certify that their products comply with the regulations and to furnish reports to the Bureau of Radiological Health which clearly substantiate the product compliance.
This document has been prepared in order to assist manufacturers in developing and implementing quality control and testing programs which are in accordance with good manufacturing practices and which assure compliance with The standard and adequacy of safeguards against hazardous electronic product radiation. Because laser products may operate over a large variety of wavelengths, emission durations, and spatial characteristics, a detailed step-by-step protocol would be of very limited application. The purpose here, therefore, is to set forth a general description of the procedures and, philosophy of quality control as appropriate for laser products, beginning from the concept and ending after final testing of the product.
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2020-D-0957.
Was bedeutet dieser Text für Ihre Situation?
Kostenlose und unverbindliche Beratung
Schildern Sie uns Ihre Situation. Unser Team meldet sich per E-Mail bei Ihnen für Ihre Beratung.
Setzen Sie Ihre Recherche in ChatGPT oder Claude fort
Verbinden Sie Omnilex, um den Rechtskorpus über Ihren KI-Assistenten zu durchsuchen.